Becton Dickinson AI Stock Analysis
Want to see BDX full AI Analyst Report?
Becton Dickinson (BDX) AI Stock Analysis
Becton Dickinson
(NYSE:BDX)
BDX scores as a mid-range opportunity driven primarily by steady fundamentals and strong cash generation, supported by a positive earnings call highlighting share gains, productivity, and improving free cash flow. The score is held back by near-term profitability/ROE pressure and a very high P/E, while technicals are positive but look overextended (high RSI/Stochastics), increasing near-term pullback risk.
Becton Dickinson Key Performance Indicators (KPIs)
Revenue by GeographyShows how Becton Dickinson’s sales are split across regions (U.S., Europe, Asia, etc.), revealing where revenue and growth are concentrated, which markets expose the company to regulatory or reimbursement risks, and how sensitive results are to currency swings.
International revenue showed sustained recovery through 2023–25 driven by biologics and other growth platforms, but the sharp drop in the most recent quarter likely reflects China market softness and the temporary shipment hold tied to an FDA warning letter, reversing momentum. Management’s guidance assumes H2 roughly similar to H1 and a modest FX tailwind, but near‑term China and logistics risks make international results the primary downside threat to meeting low-single-digit full‑year growth and margin targets.
Becton Dickinson (BDX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $58.68B
- Dividend Yield
- 1.85%
- Average Volume (3M)
- 1.82M
- Price to Earnings (P/E)
- 52.0
- Beta (1Y)
- 0.32
- Revenue Growth
- -7.40%
- EPS Growth
- -28.89%
- Country
- US
- Employees
- 60,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Becton Dickinson Business Overview & Revenue Model
Company Description
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, a...
How the Company Makes Money
BD primarily makes money by selling medical devices and consumable supplies to hospitals, clinics, laboratories, life science researchers, and pharmaceutical companies. A significant portion of revenue comes from recurring, high-volume consumables (f...
Becton Dickinson Earnings Call Summary
The call was strongly positive, supported by strong Q4 revenue and adjusted EPS growth, broad-based momentum across key platforms, share gains, improved cash flow, productivity gains, innovation progress, and a completed portfolio transformation. The main challenges were the Alaris comparison, low-single-digit fiscal 2027 revenue guidance, flat reported operating margins, inflation and tariff effects, and the Q4 vaccine decline, but management characterized several of these pressures as temporary or moderating and expressed confidence in continued growth and margin expansion beyond fiscal 2027.
Q4-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For fiscal 2027, BD expects low single-digit growth for the full year, with currency estimated to be a headwind of about 70 basis points and an approximate 200 basis points impact from the Alaris capital comparison; excluding this impact, BD expects mid-single-digit growth at the midpoint of its guidance. Adjusted operating margins are expected to be roughly flat year-over-year, the adjusted tax rate is expected to be between 16% and 17%, weighted average shares outstanding are expected to be approximately 273 million, and adjusted EPS is expected to be in a range of $13.10 to $13.30. Q1 revenue growth is expected to be at the low end of the range, the first half is expected to be in line with the midpoint of the full year guidance, and Q1 adjusted EPS is expected to be between $2.32 and $2.37, with earnings growth expected to accelerate in Q2 and the second half of the year.
Becton Dickinson Financial Statement Overview
Summary
Financials are steady but not accelerating. Cash flow is a clear strength (positive and growing TTM free cash flow, +7.79%), and leverage looks manageable with improving TTM debt-to-equity. Offsetting this, the income statement shows near-term pressure with TTM revenue down (-2.96%), net margin falling to ~4.5%, and ROE down to ~3.8%, signaling weaker profitability and returns despite stable gross/EBITDA margins.
Income Statement
62PositiveBalance Sheet
68PositiveCash Flow
71Positive| Breakdown | TTM | Sep 2026 | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.22B | 19.46B | 21.84B | 20.18B | 19.37B | 18.87B |
| Gross Profit | 9.57B | 9.21B | 9.92B | 9.13B | 8.17B | 8.48B |
| EBITDA | 4.69B | 4.61B | 4.96B | 4.82B | 4.40B | 4.41B |
| Net Income | 1.14B | 1.15B | 1.68B | 1.71B | 1.48B | 1.78B |
Balance Sheet | ||||||
| Total Assets | 50.79B | 50.79B | 55.33B | 57.29B | 52.78B | 52.93B |
| Cash, Cash Equivalents and Short-Term Investments | 733.00M | 733.00M | 859.00M | 2.30B | 1.42B | 1.17B |
| Total Debt | 16.34B | 16.34B | 19.18B | 21.59B | 16.82B | 16.95B |
| Total Liabilities | 26.11B | 26.11B | 29.94B | 31.40B | 26.98B | 27.65B |
| Stockholders Equity | 24.68B | 24.68B | 25.39B | 25.89B | 25.80B | 25.28B |
Cash Flow | ||||||
| Free Cash Flow | 2.77B | 2.69B | 2.67B | 3.07B | 2.12B | 1.66B |
| Operating Cash Flow | 3.44B | 3.37B | 3.43B | 3.80B | 2.99B | 2.63B |
| Investing Cash Flow | -994.00M | -1.05B | -818.00M | -5.51B | -716.00M | -3.23B |
| Financing Cash Flow | -2.24B | -2.16B | -3.62B | 2.09B | -1.96B | -591.00M |
Becton Dickinson Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDX, the sentiment is Positive. The current price of 215.42 is above the 20-day moving average (MA) of 205.79, above the 50-day MA of 192.29, and above the 200-day MA of 167.73, indicating a bullish trend. The MACD of 7.40 indicates Negative momentum. The RSI at 69.74 is Neutral, neither overbought nor oversold. The STOCH value of 79.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BDX.
Becton Dickinson Risk Analysis
Becton Dickinson disclosed 25 risk factors in its most recent earnings report. Becton Dickinson reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksBecton Dickinson Peers Comparison
Overall Rating
WST78Outperform
MDLN65Neutral
BDX65Neutral
ICUI64Neutral
BAX58Neutral
TFX57Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 78Outperform | $28.85B | 46.15 | 21.08% | 0.22% | 12.60% | 32.05% | |
| 65Neutral | $49.57B | 56.52 | 4.97% | ― | 11.85% | -57.19% | |
| 65Neutral | $58.68B | 52.05 | 4.64% | 1.85% | -7.40% | -28.89% | |
| 64Neutral | $4.42B | 74.27 | 2.81% | ― | -5.82% | ― | |
| 58Neutral | $13.33B | -18.63 | -11.62% | 0.16% | 5.33% | -164.67% | |
| 57Neutral | $6.33B | 19.24 | 9.74% | 0.85% | -29.30% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BDX | Becton, Dickinson and Co | 215.42 | 68.81 | 46.94% | |
| BAX | Baxter International Inc | 25.76 | 8.11 | 45.91% | |
| ICUI | ICU Medical | 176.91 | 44.34 | 33.45% | |
| TFX | Teleflex | 159.55 | 54.92 | 52.49% | |
| WST | West Pharmaceutical Services, Inc. | 414.12 | 156.98 | 61.05% | |
| MDLN | Medline, Inc. Class A | 37.68 | -3.32 | -8.10% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
